Amgen submits sBLA to FDA for BLINCYTO

Amgen announced earlier this week that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) that will include new information to support the treatment of pediatric and adolescent patients who have been diagnosed with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read More »